DE2113215C2 - Verwendung von β-Sitosteryl-glykosiden und/oder -glykosidestern zur Behandlung der Prostatahyperplasie - Google Patents
Verwendung von β-Sitosteryl-glykosiden und/oder -glykosidestern zur Behandlung der ProstatahyperplasieInfo
- Publication number
- DE2113215C2 DE2113215C2 DE2113215A DE2113215A DE2113215C2 DE 2113215 C2 DE2113215 C2 DE 2113215C2 DE 2113215 A DE2113215 A DE 2113215A DE 2113215 A DE2113215 A DE 2113215A DE 2113215 C2 DE2113215 C2 DE 2113215C2
- Authority
- DE
- Germany
- Prior art keywords
- sitosteryl
- prostatic hyperplasia
- glycosides
- treatment
- glycoside esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims description 10
- 229930182470 glycoside Natural products 0.000 title claims description 10
- -1 glycoside esters Chemical class 0.000 title claims description 4
- 150000002338 glycosides Chemical class 0.000 title description 6
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- NPJICTMALKLTFW-NEOYQNEMSA-N Sitosteryl glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1OC(CO)[C@@H](O)C(O)C1O NPJICTMALKLTFW-NEOYQNEMSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010036940 Prostatic adenoma Diseases 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001205 effect on erythrocytes Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA701861A ZA701861B (en) | 1970-03-18 | 1970-03-18 | Therapeutic agent |
| ZA705627 | 1970-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2113215A1 DE2113215A1 (de) | 1971-10-07 |
| DE2113215C2 true DE2113215C2 (de) | 1985-03-21 |
Family
ID=27131005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2113215A Expired DE2113215C2 (de) | 1970-03-18 | 1971-03-18 | Verwendung von β-Sitosteryl-glykosiden und/oder -glykosidestern zur Behandlung der Prostatahyperplasie |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE764305A (OSRAM) |
| CA (1) | CA973095A (OSRAM) |
| DE (1) | DE2113215C2 (OSRAM) |
| FR (1) | FR2085718B1 (OSRAM) |
| GB (1) | GB1298047A (OSRAM) |
| IE (1) | IE35018B1 (OSRAM) |
| IL (1) | IL36438A (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA721855B (en) * | 1972-03-17 | 1973-05-30 | Liebenberg R W | Extraction of sterolins from plant material |
| JPS5123254A (en) * | 1974-08-14 | 1976-02-24 | Nippon Shinyaku Co Ltd | Suteriru beetaa dd gurukoshidono parumichinsanesuteruno seizohoho |
| GB1468473A (en) * | 1974-08-14 | 1977-03-30 | Nippon Shinyaku Co Ltd | Method for the preparation of steryl beta-d-glucoside palmitates |
| JPS51118817A (en) * | 1975-04-08 | 1976-10-19 | Nippon Shinyaku Co Ltd | A process for preparing absorbable steroid glycoside pharmaceutical |
| FR2312257A1 (fr) * | 1975-05-28 | 1976-12-24 | Nippon Shinyaku Co Ltd | Produits pharmaceutiques a action hemostatique comprenant des steryl-b-d-glucosides et leurs monopalmitates |
| DE2659466A1 (de) * | 1976-12-30 | 1979-02-15 | Roecar Holdings Nv | Steroline und deren verwendung |
| DE2759171A1 (de) * | 1977-12-31 | 1979-07-12 | Roecar Holdings Nv | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor |
| US4254111A (en) * | 1978-07-05 | 1981-03-03 | Roecar Holdings (Netherlands Antilles) Nv | Sterolin products |
| DE3401178A1 (de) * | 1984-01-14 | 1985-07-18 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | Verwendung von phytosterolglykosiden zur behandlung erhoehter 5(6)(alpha)-epoxicholesterolspiegel |
| DE3416112A1 (de) * | 1984-04-30 | 1985-10-31 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren |
| ATE142883T1 (de) * | 1991-03-28 | 1996-10-15 | Rooperol Na Nv | Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren |
| US5998396A (en) * | 1996-11-05 | 1999-12-07 | Riken Vitamin Co., Ltd. | Oil solubilized solutions and foods containing phytosterols and process for their production |
| FI974648L (fi) | 1997-09-09 | 1999-05-06 | Raisio Benecol Oy | Hydroksihappo-, maitohappo- ja hydroksialkanoaattiesterit ja niiden käyttö |
| US6267963B1 (en) * | 1999-06-02 | 2001-07-31 | Kraft Foods, Inc. | Plant sterol-emulsifier complexes |
| US6190720B1 (en) * | 1999-06-15 | 2001-02-20 | Opta Food Ingredients, Inc. | Dispersible sterol compositions |
| CA2389670A1 (en) * | 1999-11-01 | 2001-05-10 | Forbes Medi-Tech Inc. | Novel glycosides comprising pentose mono-, di-, tri-, or oligosaccharides and phytosterols and/or phytostanols |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1177645A (en) * | 1966-06-10 | 1970-01-14 | Lab Du Dr Debat | Plant Extracts and Compositions Containing Same. |
| GB1248684A (en) * | 1969-01-31 | 1971-10-06 | Inst Rech S Chimiques Et Biolo | Medicinal extracts of plants of the genus prunus and a method of obtaining them |
-
1971
- 1971-03-15 IE IE329/71A patent/IE35018B1/xx unknown
- 1971-03-16 BE BE764305A patent/BE764305A/xx not_active IP Right Cessation
- 1971-03-17 FR FR7109357A patent/FR2085718B1/fr not_active Expired
- 1971-03-18 DE DE2113215A patent/DE2113215C2/de not_active Expired
- 1971-03-18 CA CA108,054A patent/CA973095A/en not_active Expired
- 1971-03-18 IL IL36438A patent/IL36438A/xx unknown
- 1971-04-19 GB GB24417/71A patent/GB1298047A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE35018B1 (en) | 1975-10-15 |
| FR2085718A1 (OSRAM) | 1971-12-31 |
| FR2085718B1 (OSRAM) | 1974-08-30 |
| CA973095A (en) | 1975-08-19 |
| IL36438A (en) | 1974-11-29 |
| GB1298047A (en) | 1972-11-29 |
| IE35018L (en) | 1971-09-18 |
| DE2113215A1 (de) | 1971-10-07 |
| IL36438A0 (en) | 1971-05-26 |
| BE764305A (fr) | 1971-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2113215C2 (de) | Verwendung von β-Sitosteryl-glykosiden und/oder -glykosidestern zur Behandlung der Prostatahyperplasie | |
| EP0775156B1 (de) | Pharmazeutische zusammensetzungen mit estra-1,3,5(10)-trien-derivaten | |
| DE69934877T2 (de) | Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen | |
| DE69125714T2 (de) | Zusammensetzung für die behandlung des humanen prostata adenokarzinom | |
| US4254111A (en) | Sterolin products | |
| EP1284273B1 (de) | Estra-1,3,5(10)-trien-3-sulfamat Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
| DE60222908T2 (de) | Neue dammaran-sapogenine, ihre verwendung als krebsmittel sowie ein verfahren zu ihrer herstellung | |
| DE69901250T2 (de) | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität | |
| DE69508068T2 (de) | Doppelbindungs-isomer von equilin erhalten durch säure-isomerisierung | |
| DE3029363A1 (de) | Saponinhaltiges praeparat, das gegen nebennieren-atrophie wirksam ist | |
| DE2645307C2 (OSRAM) | ||
| DE2900061A1 (de) | Prostaglandin-derivate | |
| DE2759171A1 (de) | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor | |
| DE69535267T2 (de) | Verwendung zur verabreichung von östrogen | |
| DE69230069T2 (de) | Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms | |
| DE2926463A1 (de) | Spiroketaline und ihre verwendung | |
| DE3401178C2 (OSRAM) | ||
| JPS625126B2 (OSRAM) | ||
| EP0707593B1 (de) | Oral estrogen wirksame ester des 14 alpha,15 alpha-methylen-estradiols | |
| EP1737880B1 (de) | 17 alpha-fluor 17 beta-hydroximinomethyl-steroide, ein verfahren zu deren herstellung und diese verbindung enthaltende pharmazeutische zusammensetzungen | |
| EP0356754B1 (de) | Transdermal anwendbare Arzneimittel mit einem Gehalt an pharmazeutisch einsetzbaren Glykosiden | |
| DE2037155A1 (OSRAM) | ||
| EP1385578B1 (de) | Verwendung von rutinen und aescinen zur behandlung aurikulärer durchblutungsstörungen | |
| WO2000014104A1 (de) | 11β-FLUORO- 7α-(14, 14,15,15,15- PENTAFLUORO-6- METHYL-10-THIA- 6-AZAPENTADECYL) ESTRA-1,3,5(10)- TRIENE-3, 17β-DIOL ALS KRISTALLINES ANSOLVAT | |
| DE1808425C (de) | 3 Oxo 17beta hydroxy 17 alpha (but 2 myl> 13 beta C tief 1 bis C tief 3 alkyl gona 4,9,11 tnene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 2167332 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 2167332 |
|
| 8181 | Inventor (new situation) |
Free format text: PEGEL, KARL HEINRICH, DURBAN, NATAL, ZA |
|
| 8127 | New person/name/address of the applicant |
Owner name: ROECAR HOLDINGS (NETHERLANDS ANTILLES) N.V., WILLE |
|
| 8128 | New person/name/address of the agent |
Representative=s name: HARMSEN, H., DR. UTESCHER, W., DR. HARMSEN, P., DI |
|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent |